We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Poseida Therapeutics Inc (PSTX) USD0.0001

Sell:$2.15 Buy:$2.20 Change: $0.1 (4.35%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Sell:$2.15
Buy:$2.20
Change: $0.1 (4.35%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Sell:$2.15
Buy:$2.20
Change: $0.1 (4.35%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which utilizes its genetic engineering platform technologies to create cell and gene therapeutics. The Company's platforms include ournon-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Its advanced product candidate, P-PSMA-101, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC), in a Phase I trial. Its first two fully allogeneic CAR-T product candidates include P-BCMA-ALLO1 and P-MUC1C-ALLO1, both are in Phase I trial. P-BCMA-ALLO1 is developed for patients with relapsed/refractory multiple myeloma. P-MUC1C-ALLO1 is being developed to treat a range of solid tumors, including breast, ovarian and other epithelial-derived cancers. In addition, the Company has several additional allogeneic programs advancing toward anticipated IND filings, including P-CD19CD20-ALLO1.

Contact details

Address:
9390 TOWNE CENTRE DRIVE, SUITE 200
SAN DIEGO
92121
United States
Telephone:
+1 (858) 7793100
Website:
https://poseida.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PSTX
ISIN:
US73730P1084
Market cap:
$131.68 million
Shares in issue:
62.70 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Eric Ostertag
    Executive Chairman of the Board
  • Mark Gergen
    President, Chief Executive Officer, Director
  • Johanna Mylet
    Chief Financial Officer
  • Brent Warner
    President - Gene Therapy
  • Kristin Martin
    Chief People and Administrative Officer
  • Devon Shedlock
    Chief Scientific Officer, Cell Therapies
  • Harry Leonhardt
    General Counsel, Chief Compliance Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.